Sign up to save your podcasts
Or
Share Experts Talk CLL #6 : First-Line CLL Changing Landscape: The German Experience
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Experts Talk CLL #6 : First-Line CLL Changing Landscape: The German Experience
A discussion between Dr. Peter Anglin and Dr. Stephan Stilgenbauer (May 2022)
In the first episode of the 2022 series, Dr. Stephan Stilgenbauer from the University of Ulm in Germany describes his experience with novel approaches in first-line CLL, focusing on BTK- and BCL2-targeted therapies. He reveals factors that impact his choice between a continuous vs fixed treatment duration therapy and practical aspects that come into play, as well as the role of MRD in routine practice.
Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON
Stephan Stilgenbauer, MD, Professor of Medicine and Medical Director, Head Early Clinical Trials Unit (ECTU), Head Division of CLL Department of Internal Medicine III, Comprehensive Cancer Center Ulm (CCCU), Germany
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.
View all episodes
By Various Topics on AML and CLL ManagementA discussion between Dr. Peter Anglin and Dr. Stephan Stilgenbauer (May 2022)
In the first episode of the 2022 series, Dr. Stephan Stilgenbauer from the University of Ulm in Germany describes his experience with novel approaches in first-line CLL, focusing on BTK- and BCL2-targeted therapies. He reveals factors that impact his choice between a continuous vs fixed treatment duration therapy and practical aspects that come into play, as well as the role of MRD in routine practice.
Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON
Stephan Stilgenbauer, MD, Professor of Medicine and Medical Director, Head Early Clinical Trials Unit (ECTU), Head Division of CLL Department of Internal Medicine III, Comprehensive Cancer Center Ulm (CCCU), Germany
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.